Formulation: A solid
Formal Name: (6S)-8-[3-(4-pyrimidinyl)-1H-pyrrolo[2,3-b]pyridin-4-yl]-1,8-diazaspiro[5.5]undecane
Purity: ≥98%
Formula Markup: C20H24N6
Formula Weight: 348,4
Shelf life (days): 1460
CAS Number: 2226507-04-4
Notes: BDP9066 is an inhibitor of Cdc42-binding kinase α (MRCKα) and MRCKβ (Kis = 0.0136 and 0.0233 nM, respectively).{66929} It is selective for MRCKα and MRCKβ over Rho-associated kinase 1 (ROCK1) and ROCK2 (Kis = 18.4 and 5.38 nM, respectively) and a panel of 115 additional kinases at 1 µM. BDP9066 has antiproliferative activity against a panel of 757 cancer cell lines (EC50s = 50 = 64 nM) and inhibits the motility of the same cells. BDP9066 (25 µg/animal) decreases average papilloma volume in a mouse two-stage model of skin carcinogenesis initiated by 7,12-dimethylbenz[a]anthracene (DMBA; Item No. 30383) and promoted by phorbol 12-myristate 13-acetate (TPA; Item No. 10008014).
Deutsch
English
